Developing a safe and effective human immunodeficiency virus (HIV) vaccine is one of the defining scientific challenges of our time. Induction of peripheral CD8 T-cell immunity to HIV did not protect against sexual exposure to HIV type 1 (HIV-1) in humans in a recent efficacy trial (11, 43) . In simian immunodeficiency virus (SIV)-macaque studies, peripheral CD8 T-cell immunity can effectively control viremia (40) but is often observed to have a transient or limited role in delaying SIV disease in macaques (32) . The gradual accumulation of immune escape at CD8 T-cell epitopes undermines the effectiveness of CD8 T-cell immunity to SIV (6, 22, 46) . It is likely that inducing mucosal CD8 T-cell immunity to HIV will be more effective at limiting viral replication during the very early phases of acute infection, prior to massive viral dissemination and destruction of large numbers of CD4 T cells (50) . The induction of multifunctional mucosal CD8 T cells by live attenuated SIV vaccination of macaques is thought to play a significant role in the success of this strategy (25, 26) ; however, it is unfortunately too dangerous for clinical trials at present.
A series of mucosal viral and bacterial HIV vaccine vectors have been studied in recent years; however, none have yet proceeded to advanced clinical trials. Live attenuated poliovirus vectors have shown promise in SIV studies, but these viruses can in rare cases revert to virulence (14) . Salmonellabased SIV vaccine vectors are able to induce CD8 T-cell responses which express the ␣4␤7 integrin mucosal homing marker when administered orally (20, 24) . However, there may be a much stronger link between concomitant genital tract immunity and immunity induced at respiratory mucosal sites compared to that induced at enteric sites (33, 38, 42) . Vesicular stomatitis virus vectors that replicate in the nasal mucosa show promise in SIV-macaque trials but are potentially neurotoxic (55) . Replication-competent adenovirus vectors have looked promising in some SHIV-macaque studies (49) but failed to provide significant protection in a recent SIV-macaque study (17) and could have similar issues of enhanced infection rates as seen in the recent efficacy trials of replication-incompetent adenovirus type 5 vectors.
A mucosal vector system that has several advantages over existing models but that is relatively unexplored is recombinant attenuated influenza viruses. Such viruses (i) have an existing reverse genetics system to readily generate and manipulate recombinant viruses (31, 34) , (ii) are effective as anti-influenza vaccines and licensed for human use (e.g., "Flumist" vaccine [9] ) with ready production capability, (iii) have robust respiratory mucosal replication that should facilitate genital mucosal immunity, and (iv) can be generated with a variety of hemagglutinin (H) and neuraminidase (N) glycoproteins, potentially enabling these viruses to be administered sequentially in prime-boost combinations to limit the effect of antivector humoral immunity (34) . Mouse-adapted recombinant influenza virus-HIV vectors have been studied in mice and demonstrated significant induction of cellular immunity at mucosal sites (8, 27, 28, 44, 48) . However, although several native influenza viruses replicate efficiently in the respiratory tracts of Asian macaque species (10, 12, 52) , no studies to date have examined the immunogenicity or efficacy of recombinant attenuated influenza virus-SIV vectors in macaques.
MATERIALS AND METHODS
Recombinant influenza A viruses. Recombinant influenza A viruses were generated using an eight-plasmid reverse genetics system as previously described (4, 31, 39, 59) . Briefly, DNA constructs containing all eight influenza virus genome segments, (including the genetically manipulated NA segments) were transfected into a coculture of 293T and Madin-Darby canine kidney (MDCK) cells. All viral RNAs and mRNAs required for assembly and rescue of recombinant virus were generated through bidirectional transcription and translation from a single template. The two mouse-adapted strains of influenza A virus used in this study, i.e., X31 (H3N2, A/HKx31) and PR8 (H1N1, A/Puerto Rico/8/ 1934), share the same six internal gene segments but differ in their expression of HA and NA genes. The use of both strains in vaccination enables the analysis of secondary CD8
ϩ T-cell responses in the absence of neutralizing antibody. The Mane-A*10-restricted CD8 ϩ T-cell epitopes KP9 (SIV Gag 164-172) (23) , KSA10 (SIV Tat 87-96 ), and KVA10 (SIV Tat 114-123 ) (53) were inserted separately into the NA stalks of the respective viruses using recombinant PCR techniques as previously described (31) (primers and conditions are available on request). Transfection supernatants were used to amplify virus in 10-day-old embryonated eggs, and the presence of recombinant virus determined using a hemagglutination assay. The retention of the correctly inserted peptide epitope within the expanded virions was confirmed by sequencing.
Macaques and SIV infections. Eleven pigtail macaques (Macaca nemestrina) were sourced from the Australian national macaque breeding facility and were free from simian retrovirus D and tuberculosis. All studies were approved by the institutional animal ethics committees. All 11 macaques expressed the common major histocompatibility complex (MHC) I allele Mane-A*10 as assessed by sequence-specific primer PCR as previously described (51) . The macaques studied are described in Table 1 . Two macaques were naïve and nine macaques were chronically infected with SIV mac251 . The infected animals had been infected for 1 to 2 years, having participated in prior vaccination/challenge experiments (19, 36, 54) , and were all primed with low-level SIV-specific CD8 T-cell responses. SIV infections were performed on naïve animals by intravenous challenge with 40 50% tissue culture infective doses of SIV mac251 as previously described (7, 19, 36) . There were no detectable levels of escape mutants for the Mane-A*10-restricted KP9 Gag epitope within the SIV mac251 stock by either cloning and sequencing or quantitative real-time reverse transcription-PCR (qRT-PCR) as described below, consistent with the virus being derived originally from nonpigtail macaques.
Infection of pigtail macaques with recombinant influenza virus-SIV. All recombinant influenza virus-SIV vaccines were administered by both intratracheal and intranasal administration of 10 8 PFU influenza virus prepared in phosphatebuffered saline to each site. Virus was atraumatically dosed in the trachea and then in the nose with a pipette. The animals were sedated with Ketamine for all procedures. Each virus (H1N1 or H3N2) was administered twice (day 0 and 28), and animals were revaccinated with the alternate subtype virus (H3N2 or H1N1) 2 to 10 months later. Successful infection with the recombinant influenza virus-SIV vaccine was monitored by analyzing influenza virus RNA in serial swabs of the upper respiratory tract during the course of infection (60) . Briefly, samples were analyzed with an SSIII qRT-PCR one-step kit (Invitrogen) with primers and probe targeting the matrix gene, using an ABI 7500 real-time PCR system (Applied Biosciences). Seroconversion to influenza A virus was assessed by a hemagglutination inhibition assay performed on serial serum samples as previously described (47) . Briefly, 25 l of H1N1 virus was incubated at room temperature with twofold dilutions of sera treated with RDE (Deka Seiken, Tokyo, Japan) for 1 h. Turkey red blood cells (25 l, vol/vol) were added, left for 30 min, and observed for hemagglutination.
Immunogenicity studies. SIV-specific CD8 T-cell responses were monitored on fresh whole blood by tetramer staining of CD3 ϩ CD8 ϩ lymphocytes using fluorescent Mane-A*10 tetrameric protein folded around either the KP9, KSA10, or KVA10 SIV peptide epitope as previously described (18, 53) . Expression of the mucosal homing marker ␣4␤7 integrin (13) was assessed by counterstaining tetramer-positive cells with fluorescent rat anti-human integrin ␤7 (BD Pharmingen, catalog no. 551082, clone FIB504). Influenza virus-specific T cells were assessed using an intracellular cytokine staining (ICS) assay on fresh blood samples by stimulation with overlapping influenza virus peptides and assessment of the specific expression of intracellular gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣) as previously described (18 sciences/Pharmingen, San Diego CA) and 10 g/ml brefeldin A (Sigma, St. Louis, MO). Cells were labeled with anti-CD3-AF700 (clone SP34-2), anti-CD4-fluorescein isothiocyanate (clone M-T477), and anti-CD8-peridinin chlorophyll protein (clone SK1); red blood cells were lysed with BD fluorescence-activated cell sorter lysing solution; and remaining leukocytes were permeabilized with BD permeabilizing solution 2 and then incubated with anti-human IFN-␥-allophycocyanin (clone B27) and anti-human TNF-␣-PeCy7 (clone mAb11) (all from BD Biosciences) and fixed with 1% formaldehyde (Polysciences, Inc., Warrington, PA). Flow cytometric data were analyzed with FloJo software version 7.2.2 and influenza virus-specific T-cell frequencies calculated as the proportion of CD4 or CD8 T cells expressing the particular cytokine molecule. Background expression of cytokines following dimethyl sulfoxide stimulation alone was generally Ͻ0.2% and was subtracted from antigen-specific levels. To map individual influenza virus peptide-specific T-cell responses, pools of 10 peptides were mapped and then individual peptides tested with fresh blood samples. A particular influenza virus NP-specific CD8 T-cell response was finely mapped by purchasing 9-to 10-mer peptides spanning an overlapping pair of 17-mer peptides and assessing cytokine expression to fresh blood incubated with peptide dilutions.
qRT-PCR assay to detect virus escape mutant K165R. As the vaccinations stimulated only SIV-specific CD8 T-cell responses that are known to be susceptible to immune escape (23), we studied escape from KP9-specific CD8 cells in the vaccinated/challenged animals 1335 and 2374. We utilized a qRT-PCR assay that specifically amplifies SIV that either is wild type (WT) at KP9 or carries the K165R mutation, which is the dominant escape mutation at this epitope as previously described and validated (41) . The assays use a forward primer specific for either the WT sequence or the K165R KP9 escape mutant sequence. Briefly, for each time point after SIV infection 10 l of RNA, extracted from EDTAanticoagulated plasma, was subjected to reverse transcription, and then cDNA was amplified by qRT-PCR using either WT or escape mutant primers specific for the SIV Gag KP9 epitope. A reverse primer and 5Ј 6-carboxyfluoresceinlabeled minor groove binding DNA probe were also added for quantification against the SIV Gag epitope RNA standards using an Eppendorf Realplex 4 cycler. Baselines were set two cycles earlier than real reported fluorescence, and the threshold value was determined by setting the threshold bar within the linear data phase. Samples amplifying after 40 cycles were regarded as negative, corresponding to Յ1.5 log 10 SHIV/SIV RNA copies/ml of plasma.
RESULTS

Influenza virus-SIV vaccination studies of macaques.
To assess the infectivity and immunogenicity of recombinant influenza virus-SIV expressing the SIV Gag KP9 epitope, we inoculated two naïve pigtail macaques, which expressed the Mane-A*10 allele (animals 1335 and 2374), with 10 8 PFU of recombinant H1N1 influenza virus (PR8)-SIV via the respiratory tract twice at a 4-week interval. Swabs of the respiratory tract were analyzed for influenza virus RNA daily. Influenza virus RNA was recovered from both animals at multiple sites after the first inoculation (Fig. 1A) . Virus levels peaked at 1 to 2 days after inoculation and were cleared by day 7. Two days after a second inoculation with the same virus on day 28, no RNA was detected. This suggests both (i) an adaptive immune response generated to the initial infection and (ii) that the detection of influenza virus RNA after the first inoculation was due to replicating virus and not to sampling of the inoculum. To evaluate humoral recognition of influenza virus, we analyzed serial serum hemagglutination inhibition titers against the homologous parent H1N1 virus and observed a uniform seroconversion within 7 days of inoculation (Fig. 1B) . The second inoculation did not further boost antibody levels.
To determine immunogenicity against the inserted SIV epitope, we analyzed serial fresh blood samples for the presence of KP9-specific T cells using the Mane-A*10/KP9 tetramer. We observed a small but clearly detectable KP9-specific CD8 T-cell response after the initial inoculation (Fig. 1C) . This response was marginally boosted after the second inoculation. The minimal boosting is consistent with humoral influenza virus immunity limiting replication of the vector.
Influenza virus-SIV vaccination of SIV-infected macaques. To further characterize the immunogenicity of influenza virus- SIV vaccination of pigtail macaques, we conducted additional influenza virus-SIV vaccination studies of a series of eight Mane-A*10 ϩ SIV-infected macaques used in prior therapeutic vaccine studies (Table 1 ). The macaques were infected with SIV mac251 1 to 2 years previously and had primed KP9-specific CD8 T-cell responses, and so they could be used to assess the immunostimulatory capacity of recombinant influenza virus-SIV prime-boost regimens. We studied two prime-boost regimens, each with four animals, with two doses of H1N1 influenza virus-SIV vaccination followed by two doses of H3N2 influenza virus-SIV vaccination or vice versa (Table 1 ; Fig. 2) . As with the infection of the naïve animals, influenza virus RNA was recovered from the respiratory tracts of infected animals, and all animals seroconverted to influenza virus (data not shown). Both regimens were effective in reboosting KP9-specific CD8 T cells (Fig. 2) . Following the H1N1-SIV prime/ H3N2-SIV boost regimen, three of the four animals (animals 5821, 5827, and 086B) had substantial expansion of KP9-specific CD8 T cells, i.e., up to 10% of all CD8 T cells after the initial H1N1 influenza virus-SIV vaccination (Fig. 2A) . These very large responses were not substantially reboosted by subsequent immunization with the H3N2-SIV virus. The four animals receiving first the H3N2 influenza virus-SIV recombinant virus had a more modest expansion of KP9-specific CD8 T cells after the initial vaccination (to ϳ0.5%) (Fig. 2B) , although these cells reexpanded to similar levels after the H1N1 boost. These studies suggest that SIV-specific CD8 T cells can be boosted by influenza virus-SIV vaccination of SIV-infected animals and that prime-boost immunization with heterologous influenza virus strains can maintain high levels of SIV-specific T cells.
Characterization of influenza virus-specific CD8 T cells. The limited expansion of SIV-specific CD8 T cells following boosting with a heterologous influenza virus-SIV vector suggested that adaptive immune responses to influenza virus other than antibody responses could play a role in reducing the effectiveness of the boost. We therefore assessed serial fresh blood samples for influenza virus-specific T-cell responses by ICS throughout the course of the influenza virus-SIV vaccination study. To our knowledge, influenza virus-specific T-cell immunity has not previously been analyzed in pigtail macaque models or mapped in any macaque model. We studied responses to influenza virus NP and M1. These proteins are conserved for both the H1N1 and H3N2 strains used for vaccination, and NP is a common target for CD8 T-cell immunity in both mice and humans (57, 58) . The majority of animals vaccinated with the recombinant influenza virus-SIV generated antiviral cytokine-producing CD8 and CD4 T cells in response to restimulation with overlapping peptides of NP (Fig. 3) . T-cell responses to M1 protein were much smaller and less common (not shown). NP-specific CD8 T-cell responses begin to appear at day 35 following two doses of the initial recombinant influenza virus strain and were further boosted following one dose of the alternate heterologous recombinant influenza virus strain (Fig. 3A and C) . A similar trend was observed for the generation of NP-specific CD4 T cells (Fig. 3B and D) .
The reasonably robust T-cell responses to the whole influenza virus NP peptide pool suggested that the immune response in these pigtail macaques could target common NP epitopes. We therefore used smaller sets of 10 overlapping peptides to map CD4 and CD8 T-cell epitopes of NP and M1. The influenza virus-specific CD4 and CD8 T-cell epitopes mapped to individual peptides are shown in Table 1 . During epitope mapping analysis of one animal (2374), peptides 80 and 81 of NP (NP 401-423 ) stimulated a robust response CD8 T-cell response encompassing the majority of the IFN-␥ and TNF-␣-producing CD8 T cells to NP (Fig. 4A) .
To finely map the NP-specific CD9 T-cell epitope, we purchased seven smaller peptides across this epitope and performed an ICS experiment on fresh blood from animal 2374 using reducing titrations of each peptide. The minimal epitope, being the smallest peptide that did not titrate out, was a 9-mer (SP9, NP 402-410 ) (Fig. 4B) . Defining this macaque influenza virus-specific CD8 T-cell epitope allowed us to screen blood samples from other influenza virus-SIV-infected macaques. A response to this NP epitope was common to four other vaccinated animals (Fig. 4A) . These animals all share the MHC I allele Mane-A*10 but not any other MHC I alleles typed for, suggesting that the observed shared response to this influenza virus CD8 T-cell epitope is restricted by Mane-A*10.
SIV challenge of influenza virus-SIV vaccinated macaques. To assess the efficacy of the influenza virus-SIV vaccination, the naïve pigtail macaques vaccinated with the influenza virus-SIV recombinants were challenged with SIV mac251 6 weeks
FIG. 2. Prime-boost vaccination of SIV-infected macaques with heterologous influenza virus-SIV vaccines. Groups of four
Mane-A*10-expressing pigtail macaques with chronic SIV infection were administered either two doses of H1N1 influenza virus-KP9 SIV vaccine followed by two doses of H3N2 influenza virus-KP9 SIV vaccine (A) or two doses of H3N2 influenza virus-KP9 SIV vaccine followed by two doses of H1N1 influenza virus-KP9 SIV vaccine (B). SIV Gag KP9-specific CD8 T cells in blood were assessed by KP9/Mane-A*10 tetramer staining, shown as a proportion of total CD8 T cells.
after the final vaccination. Both animals became infected, and acute SIV viral loads at 10 to 21 days after infection ranged from 5.52 to 6.88 log 10 copies/ml (mean of 6.62 at day 14) (Fig.  5A ). This is not significantly lower than the mean (Ϯ standard deviation) day 14 SIV viral load of 7.07 Ϯ 0.54 log 10 copies/ml for 36 unimmunized historical control animals infected with the same SIV mac251 stock (19) . Levels of SIV viremia beyond acute infection remained high at 5 to 6 log 10 copies/ml in influenza virus-SIV-immunized animals (mean, 5.60 log 10 copies) and similar to that in historical control animals (mean Ϯ standard deviation, 5.40 Ϯ 1.08 log 10 copies/ml [36] ). Consistent with the high levels of continuing viremia, a gradual peripheral CD4 T-cell depletion ensued (Fig. 5B) .
Recall responses to the SIV KP9 epitope were studied with serial blood samples. After challenge with SIV mac251 , a massive boosting of KP9-specific T cells to 8 to 10% of all CD8 T cells was observed in both macaques, demonstrating effective priming of this response (Fig. 5C) .
Immune escape from SIV-specific CD8 T cells induced by influenza virus-SIV vaccines. The high levels of viremia in the context of a very large recall CD8 T-cell response to SIV KP9 suggest that rapid early immune escape may have undermined the narrow SIV-specific immunity induced by vaccination. As the vaccination stimulated only SIV-specific CD8 T-cell responses that are known to be susceptible to immune escape (23), we studied escape from KP9-specific CD8 cells in the vaccinated/challenged animals, 1335 and 2374. Serial plasma samples were analyzed using a novel qRT-PCR that quantifies both WT viremia and the dominant K165R escape mutant viremia (41) . We observed rapid early escape at the KP9 epitope in both animals (Fig. 5E ). The escape mutant strain was first detected 10 to 14 days after challenge, and the level of the escape mutant virus exceed that of WT virus 5 weeks after infection and dominated the viral population thereafter.
Induction of ␤7 integrin-expressing SIV-specific CD8 T cells by influenza virus-SIV vaccination. The ␣4␤7 integrin is a specific mucosal homing marker on CD8 T cells. Other groups have demonstrated its role in mucosal homing of CD8 T cells in macaque models of SIV and other virus infections (13, 35) . As the animals were immunized with the influenza virus-SIV recombinants via the respiratory tract, we analyzed the expression of the ␤7 subunit on peripheral KP9-specific CD8 T cells. Both after vaccination and immediately after SIV challenge, 40 to 60% of KP9-specific T cells expressed the ␤7 surface integrin molecule (Fig. 5D) . Interestingly, a sharp transient decline in ␤7 expression on circulating KP9-specific T cells was observed at day 14, temporally associated with a dramatic increase in the CD8 T-cell response after challenge.
Expanded SIV antigen coverage with influenza virus-SIV vaccines. Vaccines that stimulate a single CD8 T-cell epitope can provide valuable information for that population of CD8 T cells; however, they (i) are unlikely to adequately model vaccines that express multiple antigens and (ii) leave the host susceptible to immune escape (as we observed above). We therefore constructed influenza virus-SIV recombinants expressing two additional recently described Mane-A*10-restricted SIV CD8 T-cell epitopes located in the Tat protein (KSA10 and KVA10) (53), H1N1-KSA10 and H1N1-KVA10. 
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We immunized a Mane-A*10 ϩ SIV-infected macaque with 10 8 PFU of each virus simultaneously via the respiratory tract.
There was a significant boost in CD8 T cells specific for all three SIV epitopes, particularly KP9 and KSA10 and to a lesser extent KVA10 (Fig. 6 ). This provides a model for the induction of broader SIV-specific CD8 T cells by mucosally administered vaccination.
DISCUSSION
Improved vaccines to prevent or ameliorate HIV infection are needed. We constructed a series of H1N1 and H3N2 recombinant influenza virus-SIVs and showed that these viruses can infect pigtail macaques via the respiratory mucosa and induce or boost SIV-specific CD8 T-cell responses. The SIVspecific CD8 T-cell responses expressed the ␣4␤7 integrin mucosal homing marker and were boosted substantially after SIV challenge. Unfortunately, the SIV-specific CD8 T cells induced by the vaccines to a single SIV epitope rapidly selected for immune escape viral mutants, and no protection against chronic SIV infection was observed, illustrating that broad immunity will be required to control such viruses. Although we also show that it is possible to boost responses to at least three SIV-specific CD8 T-cell responses using panels of recombinant influenza virus-SIV recombinants, the breadth of immunity required to adequately limit virus replication is not yet clear. Our work with macaques on this novel mucosa-based vaccine platform provides opportunities to probe the requirements for effective mucosal T-cell immunity to viruses such as HIV.
Our study significantly expands on previous mouse work on recombinant influenza virus-HIV vaccine concepts (27, 28, 44, 45, 48) . Murine studies showed the potential for recombinant influenza virus vaccines to be used in combination with other vaccine vectors (27, 28, 44) . In our macaque trials we investigated sequential administration of heterologous influenza A virus strains and showed some boosting of CD8 T cells to the inserted SIV epitope. A potential limitation of this approach is the induction of cross-reactive influenza virus-specific T-cell immunity induced by the initial immunization that limits the effectiveness of the boosting vector. Indeed, we show that influenza virus-specific CD4 and CD8 T-cell immunity was readily induced in macaques with this immunization strategy. Further, we identified and finely mapped a common influenza virus NP CD8 T-cell epitope presented by multiple pigtail macaques. This facilitates the identification and characterization of influenza virus-specific CD8 T cells and allows future comparative studies of the effectiveness of CD8 T cells to acute (influenza virus) and chronic (SIV) viruses in pigtail macaques.
We studied mouse-adapted PR8 and X31 influenza A virus strains; these attenuated strains did not cause any symptoms and were cleared within 1 week of inoculation. Rapid clearance of the vector may have resulted in more transient SIVspecific immunity, although most vector-based vaccines, other than persistent viruses such as retroviruses and herpesviruses (15, 30) , will be eliminated relatively quickly. The use of nonmouse-adapted influenza A virus strains with higher replicative capacity in primates should provide more robust and durable immunity that may not require frequent reboosting but could come at the cost of some symptoms or disease (12) . The effectiveness of recombinant vaccines based on cold-adapted strains such as those used in the licensed live attenuated influenza virus vaccines requires further study. A key practical advantage of recombinant influenza virus-HIV vaccines is the ready availability of technologies, manufacturing capacity, and marketing of existing cold-adapted live attenuated influenza virus vaccines. Such technologies are rarely present for other live vectors and should, when suitable vaccine candidates are generated, substantially speed the development of this technology into clinical trials.
The ability to induce mucosal immunity is widely viewed as essential for improved HIV vaccine efforts. Influenza virus vectors delivered to the upper respiratory tract in mice robustly induce genital mucosal T-cell immunity (33) . Our studies of the induction of SIV-specific CD8 T cells expressing the mu- cosal homing integrin ␣4␤7 suggest that similar levels of genital mucosal immunity could be induced by influenza virus-HIV vector vaccines, although future biopsy-or autopsy-based studies are needed to confirm the presence and function of elevated numbers of mucosal SIV-specific T cells. The levels of ␣4␤7 expression on circulating SIV-specific CD8 T cells are similar to those observed following live attenuated SIV infection (where virus also replicates at mucosal sites) and were comparable, if not better, than those in previous studies using DNA or viral vector vaccines administered intramuscularly (13, 35) . Interestingly, we observed a sharp decline in peripheral ␤7 ϩ SIV-specific CD8 T cells during acute SIV infection. One interpretation of this observation is that the ␤7 ϩ /tetramer-positive cells have left the circulation and headed toward SIV-infected mucosal tissues. If we can subsequently show that circulating ␤7 ϩ /tetramer-positive CD8 T cells do indeed accumulate rapidly in mucosal sites by sampling tissues in expanded studies, this could be indicative of an effective mucosal vaccination strategy. An alternative and more worrisome explanation, however, could be the specific targeting of ␣4␤7-expressing CD8 T cells by SIV. Recent observations show that this integrin can bind HIV-1 and act as a facilitator of HIV-1 dissemination (5). CD4, rather than CD8, T cells are usually targeted by HIV/SIV infection; however, future studies should examine the infectivity of these T-cell populations. An "Achilles heel" of CD8 T cell-based vaccine strategies is mutational escape (6, 29) . Vaccinating with influenza virus recombinants expressing only a single SIV CD8 T-cell epitope (KP9, SIV Gag 164-172 ) resulted in early, rapid, and complete immune escape of target virus using our novel qRT-PCR assay for the canonical K165R escape variant. Although escape may come at a "fitness cost" to the virus, this must have less impact on viral replication than effective CD8 T-cell immunity. The consequence of our strategy of vaccinating only against the KP9 epitope was a very high level of SIV-specific T cells (ϳ10% of all CD8 T cells) after challenge directed against a now-mutated viral CD8 T-cell epitope. Previous studies of rhesus macaques have elegantly shown the limitations of narrowly directed SIV-specific CD8 T-cell immunity when escape results (1) (2) (3) 6 ). Responses to other useful subdominant CD8 T-cell epitopes may be subverted by immunodominant "monoepitope" strategies (16, 22) .
A broader representation of SIV-specific CD8 T-cell epitopes, preferably supported by SIV-specific CD4 T-helper epitopes, is clearly required to adequately control virus replication. Although we show proof of principle that at least three SIV-specific CD8 T-cell responses (one Gag response and two Tat responses, all presented by Mane-A*10) can be boosted simultaneously by this recombinant influenza virus strategy, it could be cumbersome to construct sufficient numbers of influenza virus vectors to broadly cover relevant HIV/SIV T-cell epitopes in outbred populations. Expression of whole heterologous proteins from influenza virus proteins is technically possible and has been achieved with expression of the enhanced green fluorescence protein, interleukin-2, and tuberculosis proteins (21, 37, 56) ; however, the stability of such vectors will require careful study. We are currently constructing influenza virus vectors expressing whole SIV proteins.
In summary, we illustrate some of the promise and potential pitfalls of recombinant influenza virus-HIV vaccines expressing single SIV CD8 T-cell epitopes in macaques. Administration of these vectors to the respiratory tract reliably stimulates SIV-specific CD8 T cells that express mucosal homing integrin molecules. The vectors can be used in prime-boost regimens with heterologous influenza virus strains, although the usefulness of this approach is limited to some degree by conserved anti-influenza virus T-cell immunity. However, the ultimate utility of our current influenza virus-HIV vectors as effective vaccines requires further study, as immune escape from HIV-1 or SIV at CD8 T-cell epitopes is common. This strategy allows us to test the breadth of induced T-cell immune responses that will eventually be needed in future HIV vaccine strategies.
